☰

Julie K. Jadlowsky, Ph.D. - Publications

Affiliations: 
2008 Case Western Reserve University, Cleveland Heights, OH, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff AW, Chen Z, Bennett AD, Pumphrey NJ, Jakobsen BK, Riley JL. Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. Plos Pathogens. 19: e1011853. PMID 38100526 DOI: 10.1371/journal.ppat.1011853  0.498
2023 Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Reports. Medicine. 101053. PMID 37224816 DOI: 10.1016/j.xcrm.2023.101053  0.349
2022 Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14: eabn7336. PMID 36350986 DOI: 10.1126/scitranslmed.abn7336  0.459
2021 Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, ... ... Jadlowsky JK, et al. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. The Journal of Clinical Investigation. 131. PMID 34396987 DOI: 10.1172/JCI145459  0.433
2021 Zhou Y, Maldini CR, Jadlowsky J, Riley JL. Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. The Journal of Infectious Diseases. 223: 38-45. PMID 33586770 DOI: 10.1093/infdis/jiaa223  0.491
2021 Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan A, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, et al. CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. The Journal of Clinical Investigation. PMID 33571163 DOI: 10.1172/JCI144486  0.492
2020 Jacobson JM, Jadlowsky JK, Lacey SF, Fraietta JA, Plesa G, Chono H, Lee DH, Kulikovskaya I, Bartoszek C, Chen F, Dimitri A, Levine BL, Veloso EA, Hwang WT, June CH. Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33186691 DOI: 10.1016/j.ymthe.2020.11.007  0.464
2020 Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. Clinical and Experimental Medicine. PMID 32333215 DOI: 10.1007/S10238-020-00628-1  0.469
2020 Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, ... ... Jadlowsky JK, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (New York, N.Y.). PMID 32029687 DOI: 10.1126/Science.Aba7365  0.439
2020 Xu J, Gohil M, Stadtmauer E, Fraietta J, Gonzalez V, Salas-McKee J, Jadlowsky J, Gladney W, Lamontagne A, Fesnak A, Siegel D, Levine B, Lacey S, June C, Davis M. Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells) Cytotherapy. 22: S35-S36. DOI: 10.1016/J.Jcyt.2020.03.027  0.482
2020 Gladney W, Hexner E, Salas-McKee J, Fesnak A, Jadlowsky J, Plesa G, Leskowitz R, Chew A, Dai A, Gohil M, Xu J, Siegel D, Lacey S, Davis M, June C. Pre-clinical development of multiplex-CRISPR-edited cell and gene therapy products Cytotherapy. 22: S35. DOI: 10.1016/J.Jcyt.2020.03.026  0.466
2019 Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, Fraietta JA. CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy. Human Vaccines & Immunotherapeutics. PMID 30735463 DOI: 10.1080/21645515.2019.1571893  0.462
2017 Marcucci KT, Jadlowsky JK, Hwang WT, Suhoski-Davis M, Gonzalez VE, Kulikovskaya I, Gupta M, Lacey SF, Plesa G, Chew A, Melenhorst JJ, Levine BL, June CH. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29203150 DOI: 10.1016/J.Ymthe.2017.10.012  0.458
2014 Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, Fujinaga K, Karn J. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Molecular and Cellular Biology. 34: 1911-28. PMID 24636995 DOI: 10.1128/Mcb.01013-13  0.455
2012 Richardson MW, Jadlowsky J, Didigu CA, Doms RW, Riley JL. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. Journal of Immunology (Baltimore, Md. : 1950). 189: 3815-21. PMID 22988032 DOI: 10.4049/Jimmunol.1201431  0.525
2011 Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, et al. Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5. Blood. 118: 1015-9. PMID 21068438 DOI: 10.1182/Blood-2010-05-282509  0.471
2011 Pilch-Cooper HA, Sieg SF, Hope TJ, Mercanti V, Offord R, Veazey RS, Mosier DE, Clagett B, Jadlowsky JK, Chance MR, Collman RG, Riddick NE, Hartley O, Lederman MM. Response: Absence of CCR5 intracellular pools in most CD4 and CD8 T cells Blood. 118: 1179. DOI: 10.1182/Blood-2011-05-350231  0.381
2008 Jadlowsky JK, Nojima M, Okamoto T, Fujinaga K. Dominant negative mutant cyclin T1 proteins that inhibit HIV transcription by forming a kinase inactive complex with Tat. The Journal of General Virology. 89: 2783-7. PMID 18931076 DOI: 10.1099/Vir.0.2008/002857-0  0.439
2008 Jadlowsky JK, Nojima M, Schulte A, Geyer M, Okamoto T, Fujinaga K. Dominant negative mutant cyclin T1 proteins inhibit HIV transcription by specifically degrading Tat. Retrovirology. 5: 63. PMID 18620576 DOI: 10.1186/1742-4690-5-63  0.46
2007 Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America. 104: 18631-5. PMID 18006661 DOI: 10.1073/Pnas.0702130104  0.319
Show low-probability matches.